Devices, systems and methods are provided for delivering coffee-derived volatiles to a user, particularly for the treatment of addiction. The coffee volatiles are selected and delivered by devices and systems which allow for concentrated delivery to the olfactory system of the user in a controlled manner. The olfactory system is the part of the sensory system used for smelling or olfaction. Olfaction of such coffee volatiles in this prescribed fashion stimulates the reward system of the brain such that a specific desired outcome is achieved. In some embodiments, the desired outcome is a reduction in addiction symptoms or curbing of a sensation of addiction withdrawal.

The present invention relates to wake-up management. An apparatus is provided for assessing a wake-up procedure of a sedated patient in an imaging process. The apparatus comprises an input unit, a processing unit, and an output unit. The input unit is configured to receive patient profile data and sedation data comprising information about a sedation state of the sedated patient. The processing unit is configured to apply a data-driven model to the patient profile data and sedation data of the sedated patient to estimate at least one timing in the wake-up procedure of the sedated patient. The data-driven model has been trained on a training dataset obtained from historical data of one or more patients. The training dataset comprises patient profile data and sedation data of the one or more patients as training inputs and at least one timing in the wake-up procedure of the one or more patients as training outputs. The output unit is configured to provide the at least one estimated timing. The patients reaction to the sedation medication is patient specific and also the timing of the wake up procedure is patient specific. The timing prediction may help in understanding when the patient will wake-up from the sedation and hence next steps in the workflow, such as post imaging as exiting the bore, and/or performing autonomous standing up from the patient support.

Methods are provided for acute treatment of agitation, including agitation in patients with schizophrenia or bipolar disorder, comprising administering to a subject with agitation an effective dose of a dry pharmaceutical composition comprising olanzapine, wherein the dose is administered by an intranasal delivery device that provides, following intranasal administration, (a) a mean peak plasma olanzapine concentration (C.sub.max) of at least 30 ng/mL, with (b) a mean time to C.sub.max (T.sub.max) of olanzapine of less than 0.5 hours. Dry pharmaceutical compositions and devices suitable for intranasal delivery of olanzapine are provided.

A vaporizing article, comprises a vaporizer drive circuit; one or more memories configured to store a percentage of at least one constituent in an inhalation media, one or more compensation values for at least one compensation category for the at least one constituent, and instructions; and a control circuit comprising a processor coupled with the one or more memories configured to run the instructions, the instructions configured to cause the processor to: receive a dose target for a constituent; determine whether to perform compensation for an inhalation media dose in order to ensure the dose target is met; when compensation is to be performed, determine the properly compensated inhalation media dose based on an associated compensation value for the constituent; and control the vaporizer drive circuit so as to dispense a compensated dose of the inhalation media.

Methods are provided for acute treatment of agitation, including agitation in patients with schizophrenia or bipolar disorder, comprising administering to a subject with agitation an effective dose of a dry pharmaceutical composition comprising olanzapine, wherein the dose is administered by an intranasal delivery device that provides, following intranasal administration, (a) a mean peak plasma olanzapine concentration (C.sub.max) of at least 30 ng/mL, with (b) a mean time to C.sub.max (T.sub.max) of olanzapine of less than 0.5 hours. Dry pharmaceutical compositions and devices suitable for intranasal delivery of olanzapine are provided.

In certain embodiments a light therapy system (e.g., phototherapy device), such as for treatment of Alzheimer's disease, depression, dementia, short-term memory, or for improved learning, improved athletic performance or improved cognitive performance, is provided where the light system comprises a blue light source that operates at a frequency in the range from 20 to 50 Hz (preferably around 40 Hz), whereby the system enables retinal ganglion cells of a human to be exposed in order to stimulate brain waves (gamma oscillations in the human's brain).

Formulations of nicotine-free compositions, methods of preparing and using same are disclosed. More particularly, the present disclosure relates to methods of preparing inhalable nicotine-free formulations, and to methods for treating a subject with a nicotine-free formulation for use in smoking cessation or nicotine replacement. Also disclosed is a system for controlling cravings and assisting a smoker in quitting smoking or nicotine use.

Disclosed are methods of treating depression, mania, post-traumatic stress disorder (PTSD), and various other neurologic conditions using synaptic pathway training. Methods of synaptic pathway training include, generally, achieving a favorable treatment result by activating a synaptic pathway using a pharmacologic agent, such as treating refractory symptoms of depression with ketamine, following by potentiation of the favorable result by repeatedly stimulating the activated pathway. Stimulation of a synaptic pathway may be achieved by intrinsic means, such as performance of cognitive exercised, or extrinsic means, such as by delivery of a sensory stimulus to the patient, placing a potential voltage difference across the brain or a brain region, or by placing the brain or a brain region in a magnetic field.

A method of transplanting a desired emotional state from a donor to a recipient, comprising determining an emotional state of the donor; recording neural correlates of the emotional state of the donor who is in the desired emotional state; analyzing neural correlates of the emotional state of the donor to decode at least one of a temporal and a spatial pattern corresponding to the desirable emotional state; converting said at least one of a temporal and a spatial pattern corresponding to the desirable emotional state into a neurostimulation pattern; storing the neurostimulation pattern in the nonvolatile memory; retrieving the neurostimulation pattern from the nonvolatile memory; stimulating the recipients brain with at least one stimulus modulated with the neurostimulation pattern to induce the desired emotional state in the recipient.

The invention relates to a multisensory case comprising at least one odor-diffusing device consisting of at least one odor-diffusing support and a ventilator as well as a device for generating an air flow. The odor-diffusing device and the device for generating an air flow are arranged one above the other. The invention also relates to an immersive device comprising a screen and at least two multisensory cases, each case comprising at least one device for generating air flows and a sound-generating device, and to a control device designed to manage the emission of sound and air by independently controlling each of the cases.